Global Infliximab and biosimilar Market Size By Type (Infliximab, infliximab-dyyb), By Application (Crohn's Disease, Pediatric Crohn's Disease), By Region, And Segment Forecasts, 2023 to 2032

The Global Infliximab and Biosimilar Market was valued at USD 11.3 billion in 2023 and is projected to surpass USD 21.7 billion by 2031, growing at a CAGR of 8.3% during the forecast period of 2023–2031. Market growth is driven by the increasing prevalence of autoimmune diseases such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis, coupled with the rising adoption of cost-effective biosimilars. The expiration of biologic patents, favorable regulatory environments, and increasing healthcare expenditure worldwide are accelerating the shift toward biosimilars, especially in developing economies.

Drivers:

Rising Prevalence of Autoimmune Disorders

A significant surge in the incidence of chronic autoimmune diseases globally has driven the demand for infliximab and its biosimilars. Conditions such as ankylosing spondylitis, psoriasis, and Crohn’s disease are increasingly being treated with biologics, creating sustained market demand.

Cost-Effectiveness and Patent Expirations

As original infliximab biologics lose patent protection, biosimilars offering similar efficacy at lower costs are rapidly entering the market. This affordability is improving patient access and spurring healthcare systems to switch to biosimilar alternatives.

Supportive Regulatory Frameworks

Regulatory bodies such as the FDA and EMA have streamlined approval pathways for biosimilars, encouraging more players to enter the market and enhance competition.

Restraints:

Complex Manufacturing Process

The production of biosimilars requires highly controlled environments and significant technical expertise, leading to high manufacturing costs and limited manufacturer capability.

Physician Reluctance and Brand Loyalty

Despite clinical equivalency, some healthcare professionals remain hesitant to switch from branded biologics to biosimilars, especially in regions with conservative medical practices.

Opportunity:

Untapped Emerging Markets

Countries in Latin America, Asia-Pacific, and the Middle East present considerable growth opportunities due to increasing healthcare access, awareness, and rising chronic disease prevalence.

Strategic Collaborations and Licensing Agreements

Pharmaceutical companies are entering strategic alliances to expand their biosimilar portfolios and enhance market reach, particularly in regions with rising demand and fewer competitors.

Market by System Type Insights:

The market is segmented into Original Biologic (Infliximab) and Biosimilar Infliximab. In 2023, the Biosimilar Infliximab segment held the largest share and is expected to witness the fastest growth during the forecast period. Lower price points, expanding approval across indications, and increasing acceptance among prescribers are driving this dominance.

Market by End-use Insights:

Based on end-use, the market is categorized into Hospitals, Specialty Clinics, and Pharmacies. Hospitals led the market in 2023, accounting for more than 45% of total revenue due to widespread usage in intravenous treatment settings. However, specialty clinics are expected to grow rapidly as outpatient biologic administration becomes more common.

Market by Regional Insights:

North America dominated the global market in 2023 due to high disease prevalence, advanced healthcare infrastructure, and strong penetration of biosimilars. Meanwhile, the Asia-Pacific region is projected to grow at the highest CAGR through 2031. Rising healthcare investments, regulatory reforms, and growing biosimilar production capacity are key regional drivers.

Competitive Scenario:

Key players in the Global Infliximab and Biosimilar Market include Johnson & Johnson (Remicade), Pfizer Inc. (Inflectra), Celltrion Healthcare (Remsima, Truxima), Samsung Bioepis (Renflexis), and Amgen Inc. These companies are investing heavily in R&D, expanding biosimilar portfolios, and engaging in cross-border licensing and marketing collaborations.

Key Market Developments:

In 2023, Celltrion Healthcare announced expanded regulatory approval for Remsima SC in multiple countries for the treatment of Crohn’s disease and ulcerative colitis.

Pfizer launched a digital outreach program in 2024 to increase biosimilar education among prescribers in Latin America.

Samsung Bioepis signed a licensing agreement in 2025 with a Japanese pharmaceutical firm to distribute Renflexis across East Asia.

Scope of Work – Global Infliximab and Biosimilar Market

FAQs:

1) What is the current market size of the Global Infliximab and Biosimilar Market?

The market was valued at USD 11.3 billion in 2023.

2) What is the major growth driver of the Global Infliximab and Biosimilar Market?

The increasing prevalence of autoimmune diseases and the growing adoption of cost-effective biosimilars are key growth drivers.

3) Which is the largest region during the forecast period in the Global Infliximab and Biosimilar Market?

North America held the largest market share in 2023, while Asia-Pacific is expected to grow fastest during the forecast period.

4) Which segment accounted for the largest market share in the Global Infliximab and Biosimilar Market?

The Biosimilar Infliximab segment accounted for the largest share in 2023.

5) Who are the key market players in the Global Infliximab and Biosimilar Market?

Key players include Johnson & Johnson, Pfizer Inc., Celltrion Healthcare, Samsung Bioepis, and Amgen Inc.